scholarly journals Possibility of the use of serological method for the determination of immunoglobuline a antibody against early antigene of Epstein-Barr virus as a marker in the diagnosis of nasopharyngeal tumors

2005 ◽  
Vol 62 (10) ◽  
pp. 739-744 ◽  
Author(s):  
Svetlana Stosic-Divjak ◽  
Vojko Djukic ◽  
Zeljko Petrovic ◽  
Vladimir Nesic ◽  
Alek Racic ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Laryngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Blood Donors ◽  
Close Association ◽  
Undifferentiated Carcinoma ◽  
Control Groups ◽  
Serological Method ◽  
Barr Virus ◽  
Epstein Barr

Background/Aim. According to the data from immunological, biological and molecular researches, there is a close association between the undifferentiated carcinoma of nasopharyngeal type (UCNT) and Epstein-Barr virus (EBV). To use IgA EA antibody as a serological marker in our patients with nasopharyngeal carcinoma from a clinical viewpoint. Methods. 91 patients were followed in the period from 1989?1998. In 11 of the patients the antibody titre serum for the early antigen of EBV virus were determinated before the treatment, and in 24 of the patients 3 years after the treatment. There were three control groups of patients: 20 voluntary blood donors, 26 patients with squamocellular laryngeal carcinoma, and 10 patients with squamocellular nasopharyngeal carcinoma. Results. In the group of 11 patients with UCNT before the treatment, the value of anti-EA IgA titre was 31.09, and in the patients after the treatment anti-EA IgA antiody titre was 14.56. In the control groups of patients the results were: in the blood donors 5.00; in the group with the diagnosis of squamocellular laryngeal carcinoma, the titre was 5.00; in the patients with squamocellular nosopharyngeal carcinoma, the titre anti-EA IgA was 5.36. Conclusion. These results were statistically highly significant (p < 0.01). Our research clearly showed that anti-EA IgA EBV marker could be useful in diagnosing, differential diagnosing and prognosing as well.

Antibodies to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma and control groups

1987 ◽  
Vol 23 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Jen-Yang Chen ◽  
Chien-Jen Chen ◽  
Mei-Ying Liu ◽  
Show-Mei Cho ◽  
Mow-Ming Hsu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Control Groups ◽  
Barr Virus ◽  
Epstein Barr ◽  
And Control

Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients

2002 ◽  
Vol 67 (3) ◽  
pp. 359-363 ◽  
Author(s):  
Bruce M. Whitney ◽  
Anthony T.C. Chan ◽  
Alan B. Rickinson ◽  
Steven P. Lee ◽  
C.K. Lin ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
T Lymphocytes ◽  
Cytotoxic T Lymphocytes ◽  
Epstein Barr Virus ◽  
Blood Donors ◽  
Barr Virus ◽  
Southern Chinese ◽  
Epstein Barr

Anti-Epstein Barr Virus Antibody in Nasopharyngeal Carcinoma

1974 ◽  
Vol 83 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Mow-Ming Hsu ◽  
Jwo-Farn Chiou ◽  
Brian F. McCabe
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Geometric Mean ◽  
Stage Iv ◽  
Stage I ◽  
Clinical Staging ◽  
Control Groups ◽  
Barr Virus ◽  
Significant Difference ◽  
Epstein Barr

A retrospective study of anti-Epstein Barr virus (anti-EBV titers) in the sera of 400 patients with nasopharyngeal carcinoma (NPC) in Taiwan according to the clinical staging system of American Joint Committee is reported. Of NPC patients, 60% were seropositive (> 1:1640), while such values occurred only in 17.7, 10.9 and 20.6% respectively of normal adults, inflammatory diseases of the nose and throat, and head and neck tumor patients other than NPC (control groups). The geometric mean titer was 1:404 in NPC patients, and 1:116, 1:80 and 1:125 respectively in the three control groups. When 321 patients were staged, the seropositive rate increased successively from 12.5% in Stage I to 77.2% in Stage IV. Statistically, Stage I NPC patients had the same titer as the three control groups and a highly significant difference in chi-square tests from those in other stages. Radiotherapy did not influence the anti-EBV titers much; however, there was a definite decrease of titers in patients 7–18 months postradiotherapy. Thirty patients with recurrent disease and 28 patients with distant metastases demonstrated high positive titers and high geometric mean titers falling between those in Stage III and Stage IV. The correlation between EBV and NPC is discussed.

Studies of Epstein-Barr Virus Antigens Using Immunoperoxidase and Immunofluorescence Techniques

1975 ◽  
Vol 33 ◽  
pp. 342-343
Author(s):  
R. Stephens ◽  
K. Traul ◽  
D. Woolf ◽  
P. Gaudreau
Keyword(s):  
Electron Microscopy ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
If Technique ◽  
Infected Cells ◽  
Virus Antigens ◽  
Epstein Barr ◽  
Virus Capsid Antigen ◽  
Antigen Reactivity

A number of antigens have been found associated with persistent EBV infections of lymphoblastoid cells. Identification and localization of these antigens were principally by immunofluorescence (IF) techniques using sera from patients with nasopharyngeal carcinoma (NPC), Burkitt lymphoma (BL), and infectious mononucleosis (IM). Our study was mainly with three of the EBV related antigens, a) virus capsid antigen (VCA), b) membrane antigen (MA), and c) early antigens (EA) using immunoperoxidase (IP) techniques with electron microscopy (EM) to elucidate the sites of reactivity with EBV and EBV infected cells.Prior to labeling with horseradish peroxidase (HRP), sera from NPC, IM, and BL cases were characterized for various reactivities by the indirect IF technique. Modifications of the direct IP procedure described by Shabo and the indirect IP procedure of Leduc were made to enhance penetration of the cells and preservation of antigen reactivity.

Radio-Susceptibility of Nasopharyngeal Carcinoma: Focus on Epstein- Barr Virus, MicroRNAs, Long Non-Coding RNAs and Circular RNAs

2020 ◽  
Vol 13 (3) ◽  
pp. 192-205 ◽  
Author(s):  
Fanghong Lei ◽  
Tongda Lei ◽  
Yun Huang ◽  
Mingxiu Yang ◽  
Mingchu Liao ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Regulatory Networks ◽  
Epstein Barr Virus ◽  
Molecular Mechanisms ◽  
Acquired Resistance ◽  
Treatment Strategies ◽  
Circular Rnas ◽  
Barr Virus ◽  
Non Coding Rnas ◽  
Epstein Barr

Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. As a neoplastic disorder, NPC is a highly malignant squamous cell carcinoma that is derived from the nasopharyngeal epithelium. NPC is radiosensitive; radiotherapy or radiotherapy combining with chemotherapy are the main treatment strategies. However, both modalities are usually accompanied by complications and acquired resistance to radiotherapy is a significant impediment to effective NPC therapy. Therefore, there is an urgent need to discover effective radio-sensitization and radio-resistance biomarkers for NPC. Recent studies have shown that Epstein-Barr virus (EBV)-encoded products, microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), which share several common signaling pathways, can function in radio-related NPC cells or tissues. Understanding these interconnected regulatory networks will reveal the details of NPC radiation sensitivity and resistance. In this review, we discuss and summarize the specific molecular mechanisms of NPC radio-sensitization and radio-resistance, focusing on EBV-encoded products, miRNAs, lncRNAs and circRNAs. This will provide a foundation for the discovery of more accurate, effective and specific markers related to NPC radiotherapy. EBVencoded products, miRNAs, lncRNAs and circRNAs have emerged as crucial molecules mediating the radio-susceptibility of NPC. This understanding will improve the clinical application of markers and inform the development of novel therapeutics for NPC.

Sign in / Sign up

Export Citation Format

Share Document